Press Room

AAPS 2022 PharmSci 360

Start
Sunday, October 16, 2022 - 09:00
End
Wednesday, October 19, 2022 - 17:00
Location: Boston, United States
Booth Number: 1043

Visit Hovione’s booth at AAPS PharmSci 360 next October 16-19 in Boston and meet our team of experts.

 

Hovione´s pragmatic approach to bridging science with manufacturing is now being leveraged for continuous tableting.

Continuous tableting is suited for all type of drug products for oral delivery, including the production of precision medicines and breakthrough therapies. This technology assures robust supply of quality product through enhanced process control strategies while using the same equipment for development and commercial-scale production.

 

Hovione presentation with Luis Sobral at AAPS

HOVIONE PRESENTATION

On October 17th, don't miss our presentation: “Accelerate Manufacturing Processes Development with Computational Chemistry” with Luís Sobral, Fellow Scientist.

10:00 AM - 10:30 AM ET

 

Poster Sessions

Monday, October 17, 2022 | 2:30 PM – 3:30 PM ET
Poster: Use of PAT Tools in the Development, Monitor and Control of Continuous Manufacturing Processes
Presenting Author: Ricardo Sousa, MS - Senior Formulation Development Scientist, Hovione

Tuesday, October 18, 2022 | 9:30 AM – 10:30 AM ET
Poster: Enhancing the “Right First Time” Concept in Continuous Manufacturing–Development Strategy
Presenting Author: Ricardo Sousa, MS - Senior Formulation Development Scientist, Hovione

Tuesday, October 18, 2022 | 11:30 AM – 12:30 PM ET
Poster: Recent Advances in ASD Formulations: HIPROS and Dispersome
Presenting Author: Inês Ramos, PhD - Formulation Scientist, Hovione
 

 

 

Let’s discuss your project together.
Schedule a meeting with our experts.

 

 

Also in the Press Room

See All

Continuous Tableting (CT) is defined as continuous manufacturing of oral dose drugs, specifically tablets. As per ICH's Q13 definition1, a continuous manufacturing process in the pharmaceutical industry comprises at least two unit operations integrated from a mechanical and software perspective. There is a wide combination of possible CT process configurations that are dependent on the needs of the intended product formulation and each of the individual unit operations that constitute the process train can be continuous, semi-continuous, or batch processes. The typical manufacturing processes for tablet formulation are direct compression (DC), dry granulation (DG) and wet granulation (WG)2 - details on these manufacturing processes are beyond the scope of this article, so the interested reader is directed to relevant literature. The actual implementation of CT technology in a facility can broadly vary depending on the level of desired integration and automation. Process trains can be designed to be flexible and converted between multiple configurations (e.g. continuous DC, DG and WG), controlled by the end user from one single software and within a single clean room. The other possibility would be for subsections of the CT process to be divided into multiple clean rooms where inprocess materials are transferred between suites via a bin-to-bin approach (e.g. a granulation suite to prepare granules from raw materials followed by continuous DC (CDC) to blend the granules and produce tablets). The level of automation and instrumentation designed into the CT process (typically involving Process Analytical Technologies, PAT) can open the possibility to implement sophisticated control strategies. Key components of a control strategy that need to be considered for CT are material tracking and genealogy, knowledge of the residence time distribution (RTD), and in-process controls (spectroscopic and/or soft sensors based on process parameters). Holistically, these control strategy elements enable the implementation of a material diversion strategy to automatically divert out of specification material from the process. In their most advanced form, control strategies may also enable real time release testing (RTRt) of the final tablet drug product and reduce the off-line analytical burden and the number of operators needed to manage the process.   Read the full article at gmp-journal.com  

Article

Continuous Tableting and the Road to Global Adoption

Mar 04, 2024